Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mild-to-moderate Alzheimer's Disease AND ALZHEIMER Disease AND MRI

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: Mild-to-moderate Alzheimer's Disease AND ALZHEIMER Disease AND MRI. Displaying page 2 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2012-003242-33 Sponsor Protocol Number: GN28525 Start Date*: 2012-11-30
    Sponsor Name:Genentech, Inc.
    Full Title: A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY EXTENSION OF PHASE II STUDIES ABE4869g AND ABE4955g IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
    Medical condition: Mild to moderate Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011424-64 Sponsor Protocol Number: M10-984 Start Date*: 2009-11-09
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease
    Medical condition: Mild to moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-006336-94 Sponsor Protocol Number: MK-1942-008 Start Date*: 2022-10-24
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia.
    Medical condition: Alzheimer’s Disease dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10012292 Dementia of the Alzheimer's type NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001100-12 Sponsor Protocol Number: 1198.022 Start Date*: 2004-08-09
    Sponsor Name:Boehringer Ingelheim Pharma Ges mbH
    Full Title: A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week ...
    Medical condition: Mild to moderate dementia of the Alzheimer's type
    Disease: Version SOC Term Classification Code Term Level
    5 10001897 High
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-005929-11 Sponsor Protocol Number: CN156013 Start Date*: 2009-02-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Mild to Mode...
    Medical condition: ALZHEIMER DISEASE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-003151-20 Sponsor Protocol Number: 8931-017 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer?s Disease. (Phase 2/3; Protocol No. MK-8931-017-02) ...
    Medical condition: mild to moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) PT (Completed) HU (Completed) BE (Completed) AT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000986-42 Sponsor Protocol Number: A9951002 Start Date*: 2008-10-21
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF PF-04360365 IN PATIENTS WITH MILD TO MODERATE ALZHEI...
    Medical condition: MILD TO MODERATE ALZHEIMER’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001598-25 Sponsor Protocol Number: IG1002 Start Date*: 2011-10-25
    Sponsor Name:INSTITUTO GRIFOLS, S.A.
    Full Title: A multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmaphereses with infusion of human albumin combined with intra...
    Medical condition: Mild to Moderate Alzheimer's Disease patients.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002061-39 Sponsor Protocol Number: B2571004(3134K1-200-EU) Start Date*: 2007-04-19
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
    Full Title: A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant and Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Immunogenicity Trial of ACC-001 and QS-21 Adjuvant i...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015525-37 Sponsor Protocol Number: D1950C00006 Start Date*: 2010-01-27
    Sponsor Name:AstraZeneca AB
    Full Title: Safety, Tolerability and Pharmacokinetics of 3 Dose regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo controlled, Parallel group...
    Medical condition: Patients with mild to moderate Alzheimer's Desease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005549-39 Sponsor Protocol Number: EHT 0202/002 Start Date*: 2007-12-19
    Sponsor Name:EXONHIT
    Full Title: A pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIa study to determine the clinical safety/tolerability and exploratory efficacy of EHT 0202 (40 and 80 mg ...
    Medical condition: Alzheimer disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001851-11 Sponsor Protocol Number: LRP/LND101001/2013/001 Start Date*: 2015-06-19
    Sponsor Name:Lupin Atlantis Holdings S.A.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients wi...
    Medical condition: Mild to Moderate Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) LT (Prematurely Ended) PL (Completed) IT (Completed) ES (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004368-22 Sponsor Protocol Number: 221AD304 Start Date*: 2020-08-26
    Sponsor Name:Biogen Idec Research Limited
    Full Title: Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 an...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) FI (Prematurely Ended) AT (Completed) PL (Completed) PT (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002866-11 Sponsor Protocol Number: TRx-237-015 Start Date*: 2013-01-23
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-001402-92 Sponsor Protocol Number: AVA102670 Start Date*: 2006-09-06
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase in...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) FI (Completed) BE (Completed) CZ (Completed) SI (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-001475-35 Sponsor Protocol Number: 3098B1-201 Start Date*: 2006-03-23
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005778-11 Sponsor Protocol Number: NP031112-08B03 Start Date*: 2009-01-29
    Sponsor Name:Noscira S.A.
    Full Title: A 14 week double-blind, placebo-controlled, randomized, escalating dose study to evaluate the safety and tolerability of three oral doses of NP031112, a novel GSK3 inhibitor, in mild to moderate Al...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002764-27 Sponsor Protocol Number: NILVAD2012 Start Date*: 2013-02-04
    Sponsor Name:St James's Hospital
    Full Title: A European multicenre double-blind placebo controlled phase III trial of nilvadipine in mild to moderate Alzheimer's disease.
    Medical condition: Mild to Moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) GR (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005089-34 Sponsor Protocol Number: BRL-049653/461 Start Date*: 2006-09-28
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A double-blind, randomised, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilisation and cognition in subjects...
    Medical condition: Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018273-38 Sponsor Protocol Number: D1950C00011 Start Date*: 2010-03-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dos...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 29 06:24:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA